Zhengye Biotechnology Holding Limited (ZYBT)
Automate Your Wheel Strategy on ZYBT
With Tiblio's Option Bot, you can configure your own wheel strategy including ZYBT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZYBT
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.3044
- CurrentRatio 1.3065
- ROIC 0.035
- MktCap 280079299.728
- FreeCF/Share 0.0
- PFCF 21.1014
- PE 0.0
- Debt/Assets 0.1752
- DivYield 0
- ROE 0.0406
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company's research and operational milestones achieved in 2025 and outlines Zhengye's strategic priorities for growth in 2026. The full text of the letter follows.
Read More
About Zhengye Biotechnology Holding Limited (ZYBT)
- IPO Date 2025-01-07
- Website https://www.jlzybio.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Songlin Song
- Employees 278